Harmony Biosciences is showcasing WAKIX at APA 2026. Here's the context, what to ask at the booth, and where Videra fits in the conversation.
WAKIX is the only histamine-based narcolepsy treatment — differentiated from stimulants and oxybate. At APA, they'll target psychiatrists who see narcolepsy patients (often misdiagnosed as depression or ADHD) and the large overlap between narcolepsy and psychiatric comorbidities. Pediatric expansion (Feb 2026) gives them a fresh story.
Ask about: Psychiatrist's role in narcolepsy diagnosis (often the first clinician to see these patients); how WAKIX fits vs. modafinil, stimulants, and oxybate; pediatric cataplexy data; psychiatric comorbidity management in narcolepsy patients; broader pipeline plans beyond WAKIX.
VoiceVitals measures daytime alertness through vocal biomarkers — objective, continuous EDS assessment between visits that standard ESS questionnaires can't provide. ePRO+ captures caregiver-reported symptoms in pediatric narcolepsy.
Position as the outcomes monitoring tool that helps psychiatrists track WAKIX response objectively.
Set up a follow-up with Harmony Biosciences's team and Videra Health.
Email Ryan Roberts →